Form 8-K - Current report:
SEC Accession No. 0001493152-23-005890
Filing Date
2023-02-23
Accepted
2023-02-23 17:00:33
Documents
15
Period of Report
2023-02-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42766
2 ex2-1.htm EX-2. 34639
3 ex99-1.htm EX-99.1 113473
4 ex99-2.htm EX-99.2 13068
  Complete submission text file 0001493152-23-005890.txt   397199

Data Files

Seq Description Document Type Size
5 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ocx-20230216.xsd EX-101.SCH 3224
6 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ocx-20230216_lab.xml EX-101.LAB 34240
7 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ocx-20230216_pre.xml EX-101.PRE 22358
9 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3461
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

EIN.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37648 | Film No.: 23660689
SIC: 2835 In Vitro & In Vivo Diagnostic Substances